 |
|||
  
|
|
||
 |
|||
| The Principals have made investments in the following biotechnology companies: | |||
 |
|||
| AppTec Laboratory Services, Inc.
| www.apptecls.com | provides analytical testing services to the
medical device and biopharmaceutical industries and manufactures protein
therapeutics for biopharmaceutical customers. |
|||
Altair Therapeutics, Inc. | www.altairtherapeutics.com | is a biotechnology company focused on the discovery, development and commercialization of antisense drugs for respiratory conditions. |
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|
|||
Coley Pharmaceutical Group, Inc. (ticker: COLY) | www.coleypharma.com | is a leader in the research and development of Toll-like receptor drugs to modulate the immune system for treating cancer, infectious diseases and asthma/allergy. |
|||
 |
|||
| Coulter Pharmaceutical, Inc. (ticker
was CLTR; acquired by Corixa Corporation ticker: CRXA, and subsequently
acquired by GlaxoSmithKline plc ticker: GSK) | www.gsk.com | devloped therapeutic antibodies and targeted oncologics
to treat cancer. |
|||
|
|||
|
|||
 |
|||
| NeXagen, Inc. (ticker was NXGN; merged
with Vestar, Inc. to become NeXstar, Inc. with ticker NXTR and subsequently
acquired by Gilead Sciences, Inc. ticker: GILD) | www.gilead.com | utilized proprietary "combinatorial chemistry"
technology to discover lead therapeutic and diagnostic compounds. MACUGEN®,
approved for wet age-related macular degeneration, was discovered using
this technology. Upon NeXagen’s merger with Vestar, Inc., the company also
marketed and developed liposomal drug delivery products. |
|||
 |
|||
| Oxford GlycoSciences, plc (ticker was OGSI; acquired by Celltech Group plc ticker: CLL) | www.celltechgroup.com.com | was a leading technology developer in the fields of glycobiology and proteomics. Utilizing its technology, the company developed a lead pharmaceutical product Zavesca®, that was approved by the European Commission, and established proteomics collaborations with several multi-national pharmaceutical companies.
|
|||
|
|||
|
|||
 |
|||
| Transkaryotic Therapies, Inc. (ticker
was TKTX; acquired by Shire Pharmaceuticals Group PLC ticker: SHPGY) | www.shire.com |
developed novel technologies for the production of human proteins and for gene therapy systems. Products developed with these technologies include Replagal™, a drug approved for the treatment of Fabry Disease and Elaprase™, a product awaiting approval for Hunter syndrome. |
|||
|
|||
Tranzyme Pharma, Inc. | www.tranzyme.com | is a leading biopharmaceutical company developing novel small molecule therapeutics for the treatment of gastrointestinal and metabolic disorders. The Company's lead product, TZP-101, is a potent gastroprokinetic agent that recently entered a Phase I trial for acute gastrointestinal motility dysfunction. |
|||
 |
|||
| Visible Genetics, Inc. (ticker was VGIN; acquired by Bayer Corporation ticker: BAY) | www.bayer.com |developed and marketed analytical testing systems that enabled more accurate selection of pharmaceutical regimes for patients with HIV.
|
|||
|
|
|
|
|
